Averin Cap Acquisition Corp SEC Filings

Averin Capital Acquisition Corp. appointed Akiko Moni Miyashita to its board of directors, effective May 28, 2026. She will serve in the first class of directors, with a term ending at the company’s first annual general meeting.

Miyashita, age 70, is the Founder of Beacon Hill Strategy Group since October 2024 and has more than 25 years of experience in strategy, finance and corporate development across healthcare, life sciences, technology and global markets. Her prior roles include Executive Vice President and Chief Strategy Officer at Valo Health, Senior Advisor at McKinsey & Company, Partner at Innosight, and Vice President of Corporate Development at IBM.

In connection with her appointment, she joined an existing letter agreement and a registration rights agreement, agreeing to waive certain redemption rights, vote her ordinary shares in favor of an initial business combination, and receive registration rights for any company shares she owns. She also entered into a standard director indemnity agreement with Averin Capital Acquisition Corp.

Averin Capital Acquisition Corp. director Miyashita Akiko Moni has filed an initial Form 3 as a reporting person for the company. The filing does not list any share transactions or derivative positions, indicating it is a baseline disclosure of insider status rather than a record of recent trading activity.

Averin Capital Acquisition Corp. director Miyashita Akiko Moni has filed an initial Form 3 as a reporting person for the company. The filing does not list any share transactions or derivative positions, indicating it is a baseline disclosure of insider status rather than a record of recent trading activity.

Averin Capital Acquisition Corp., a SPAC focused on technology and health, reported net income of $832,500 for the three months ended March 31, 2026, mainly from $987,118 of interest on funds in its trust account. Total assets were $285.5M, including $284.8M of investments in the Trust Account backing 28,386,008 Class A shares subject to redemption at about $10.03 per share. The SPAC raised $283.9M through its IPO, over-allotment and private placement, and has a deferred underwriting fee of $15.6M payable upon completing a business combination. Management discloses substantial doubt about the company’s ability to continue as a going concern due to limited working capital and the requirement to complete a business combination by February 20, 2028 (or May 20, 2028 with a signed deal) or liquidate.

Averin Capital Acquisition Corp., a SPAC focused on technology and health, reported net income of $832,500 for the three months ended March 31, 2026, mainly from $987,118 of interest on funds in its trust account. Total assets were $285.5M, including $284.8M of investments in the Trust Account backing 28,386,008 Class A shares subject to redemption at about $10.03 per share. The SPAC raised $283.9M through its IPO, over-allotment and private placement, and has a deferred underwriting fee of $15.6M payable upon completing a business combination. Management discloses substantial doubt about the company’s ability to continue as a going concern due to limited working capital and the requirement to complete a business combination by February 20, 2028 (or May 20, 2028 with a signed deal) or liquidate.

Averin Capital Acquisition Corp. Schedule 13G reports that Adage Capital Management, L.P., together with Robert Atchinson and Phillip Gross, beneficially own 2,250,000 Class A ordinary shares, representing 8.93% of the Class A shares outstanding. The percentage is calculated on 25,200,000 shares outstanding as of February 20, 2026.

The filing states shared voting and dispositive power of 2,250,000 shares for each Reporting Person and includes a Joint Filing Agreement in Exhibit 99.1.

Averin Capital Acquisition Corp. Schedule 13G reports that Adage Capital Management, L.P., together with Robert Atchinson and Phillip Gross, beneficially own 2,250,000 Class A ordinary shares, representing 8.93% of the Class A shares outstanding. The percentage is calculated on 25,200,000 shares outstanding as of February 20, 2026.

The filing states shared voting and dispositive power of 2,250,000 shares for each Reporting Person and includes a Joint Filing Agreement in Exhibit 99.1.

Averin Capital Acquisition Corp., a blank check company listed on Nasdaq, announced that holders of its IPO units can begin separately trading the underlying securities on April 10, 2026. Each unit consists of one Class A ordinary share with a par value of $0.0001 and one-sixth of a redeemable warrant.

The Class A ordinary shares will trade under the symbol ACAA and the whole warrants under ACAAW, while any units that remain bundled will continue to trade as ACAAU. Each whole warrant allows the purchase of one Class A ordinary share at an exercise price of $11.50 per share.

Averin Capital Acquisition Corp., a Cayman Islands-based special purpose acquisition company, completed a partial exercise of the underwriters’ over-allotment option tied to its recent IPO. The underwriters purchased an additional 3,386,008 units at $10.00 per unit, adding $33,860,080 in gross proceeds.

The IPO originally sold 25,000,000 units at $10.00 per unit, and a concurrent private placement of 200,000 units to the sponsor added $2,000,000. In total, 28,386,008 public units and 200,000 private placement units have been sold for aggregate gross proceeds of $283,860,080, all largely held in a U.S. trust account. Each unit includes one Class A ordinary share and one-sixth of a redeemable warrant exercisable at $11.50 per share.

Averin Capital Acquisition Corp. shows that Sculptor-affiliated entities beneficially own 1,500,000 Class A ordinary shares, representing 5.95% of the class.

The filing states the ownership reflects shared voting and dispositive power for 1,500,000 shares across Sculptor Capital, Sculptor Capital II and related entities, calculated using 25,200,000 shares outstanding as set forth in the issuer's Form 8-K dated 02/26/2026.

Averin Capital Acquisition Sponsor LLC and related parties report beneficial ownership of 7,387,500 ordinary shares, or 20.44%, of Averin Capital Acquisition Corp. This stake consists of 200,000 Class A Ordinary Shares and 7,187,500 Class B Ordinary Shares, with 937,500 Class B shares subject to possible forfeiture.

The Class B shares are automatically convertible into Class A shares on a one-for-one basis at the initial business combination or earlier at the holder’s option. Amendment No. 1 adds Eric Berry as an additional reporting person alongside the Sponsor, Handel Rose LLC, and David Berry, who together share voting and investment discretion over the Sponsor’s holdings.

All three—Handel Rose LLC, David Berry, and Eric Berry—may be deemed to beneficially own the Sponsor’s securities but each disclaims beneficial ownership beyond any direct or indirect interests. The filing notes no transactions in the issuer’s ordinary shares by the reporting persons during the 60 days preceding the report.

Averin Capital Acquisition Sponsor LLC reported buying 200,000 Class A ordinary shares of Averin Capital Acquisition Corp. at $10.00 per share on 2025-02-20, bringing its reported Class A holdings to 200,000 shares.

The shares represent stock underlying private placement units, each unit including one Class A share and one-sixth of a warrant exercisable for an additional Class A share. The Sponsor holds these shares of record, while Handel Rose LLC controls the Sponsor. Eric Berry and David Berry may be deemed beneficial owners through Handel Rose LLC but each disclaims beneficial ownership beyond any pecuniary interest. A separate 7,187,500 Class B ordinary shares is noted, which will convert into Class A shares in connection with the company’s initial business combination or earlier at the holder’s option.

Averin Capital Acquisition Corp. reported initial insider holdings of 7,387,500 Class B ordinary shares through Averin Capital Acquisition Sponsor LLC. These Class B shares automatically convert into Class A ordinary shares on a one-for-one basis at the company’s initial business combination or earlier at the holder’s option, subject to adjustments.

The Class B shares have no expiration date and include up to 937,500 shares subject to forfeiture if the underwriters of the initial public offering do not fully exercise their over-allotment option. Handel Rose LLC controls the sponsor, and Eric Berry and David Berry may be deemed beneficial owners but disclaim ownership beyond any pecuniary interest.